Current perspectives in the treatment of advanced prostate cancer

Medical Oncology

Volumn 24, Issue 3, 2007, Pages 273-286

  Valdespino, Victor ^a   Tsagozis, Panagiotis ^b   Pisa, Pavel ^b  

^a UNIVERSIDAD AUTÓNOMA METROPOLITANA   (Mexico)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Advanced stages; Molecular therapy; Prostate cancer

Indexed keywords

AMINOGLUTETHIMIDE; BEVACIZUMAB; BICALUTAMIDE; CORTICOSTEROID; DIETHYLSTILBESTROL; DOCETAXEL; ESTRADIOL; ESTRAMUSTINE; ETOPOSIDE; FLUTAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IODINE 131; KETOCONAZOLE; LUTETIUM 177; MITOXANTRONE; NAVELBINE; NILUTAMIDE; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; SAMARIUM 153; STRONTIUM 89; UNINDEXED DRUG; VATALANIB; VINBLASTINE; YTTRIUM 90; ZOLEDRONIC ACID;

BONE MARROW TOXICITY; BONE METASTASIS; CANCER RESEARCH; CANCER STAGING; CARCINOGENESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; GENE THERAPY; GENETIC SUSCEPTIBILITY; GLEASON SCORE; HUMAN; IMMUNOTHERAPY; INCIDENCE; LEUKEMIA; MOLECULAR THERAPY; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; ORCHIECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TUMOR SUPPRESSOR GENE; UNITED STATES;

ANDROGEN ANTAGONISTS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; GENE THERAPY; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

EID: 36248945608     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-0017-9     Document Type: Review

References (112)

1. Varenhorst E, Garmo H, Holmberg L, Stattin P, Johansson JE. Prostatic cancer in Sweden 1998-2003. Drastic change of the disease panorama. Lakartidningen 2006;103:285-8.
2. Jemal A, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
4. The GLOBOCAN 2002 database . Available online at http://www-dep.iarc.fr/ globocan.
5. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50.
6. Gronberg H, Damber L, Jonson H, Damber JE. Prostate cancer mortality in northern Sweden, with special reference to tumor grade and patient age. Urology 1997;49:374-8.
7. Nelson WG, Carter HB, DeWeese TL, Bajaj GK, Thompson TL, Eisenberger MA. Prostate cancer. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, editors. Clinical oncology. Philadelphia: Elsevier Churchill Livingstone; 2004. p. 2085-148.
8. Osterling JFZ, Lee CT, Scher HI. Cancer of the prostate. In: DeVita VT Jr HS, Rosenberg SA, (editors). Cancer. Principles & practice of oncology. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 1192-268.
9. Palapattu GS, et al. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis 2005;26:1170-81. Epub 2004 Oct 1121.
10. Bostwick DG. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 1996;78:330-6.
11. Sakr WA, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-43.
12. Ribeiro FR, et al. Statistical dissection of genetic pathways involved in prostate carcinogenesis. Genes Chromosomes Cancer 2006;45:154-63.
13. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
14. Meng MV, Dahiya R. Molecular genetics. In: Carroll PR, Grossfeld GD, editor. Prostate cancer. Atlas of clinical oncology. London: BC Decker Inc.; 2002; p. 42-59.
15. Lexander H, et al. Proteomic analysis of protein expression in prostate cancer. Anal Quant Cytol Histol 2005;27:263-72.
16. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996;28:98-106.
17. Culig Z, et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996;28:392-405.
18. Gioeli D. Signal transduction in prostate cancer progression. Clin Sci (Lond) 2005;108:293-308.
19. Culig Z, Klocker H, Bartsch G, Hobisch A. Androgen receptors in prostate cancer. Endocr Relat Cancer 2002;9:155-70.
20. Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004;351:1488-90.
21. Sun C, et al. Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 2006;25:3905-13. Epub 2006 Apr 3924.
22. Sharifi N, Farrar WL. Androgen receptor as a therapeutic target for androgen independent prostate cancer. Am J Ther 2006;13:166-70.
23. Shah RB, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 2004;64:9209-16.
24. Sciarra A, et al. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma. Int J Clin Pract 2006;60:462-70.
25. Tomita K, et al. Cadherin switching in human prostate cancer progression. Cancer Res 2000;60:3650-54.
26. AJCC Cancer Staging Manual. In: Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M, editors. 6th ed. New York: Springer-Verlag; 2002.
27. Nasseri KK, Austenfeld AM. PSA recurrence after definitive treatment of clinically localized prostate cancer. AUA Update Series 1997;16:82-7.
28. Roach M, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 2000;47:609-15.
29. Chodak GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994;330:242-8.
30. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. Jama 1997;277:467-71.
31. Prostate Cancer. In: Carroll PR, Grossfeld GD, editors. Atlas of clinical oncology. Hamilton, Ontario: BC Decker Inc.;2002. p. 164-83.
32. Prostate Cancer. Clinical practice guidelines in oncology (ed v.2.2005): National Comprehensive Cancer Network. Available on the NCCN web site http://www.nccn.org.
33. Small EJ, et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol 2001;19:1304-11.
34. Debruyne FM. Design of clinical trials in advanced prostate cancer: avoiding the dead ends. BJU Int 2005;96:47-53.
35. Bubley GJ, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17:3461-7.
36. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989;141:873-9.
37. Partin AW, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43:649-59.
38. D'Amico AV, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376-83.
39. Semeniuk RC, Venner PM, North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 2006;68:565-9.
40. Sengupta S, et al. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival. J Urol 2006;175:1684-90. Discussion 1690.
41. Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
42. Partin AW, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843-8.
43. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 1999;17:1499-507.
44. Coleman CN, Beard CJ, Kantoff PW, Gelman R. Rate of relapse following treatment for localized prostate cancer: a critical analysis of retrospective reports. Int J Radiat Oncol Biol Phys 1994;28:303-13.
45. Leibel SA, et al. Technological advances in external-beam radiation therapy for the treatment of localized prostate cancer. Semin Oncol 2003;30:596-615.
46. Stephenson AJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. Jama 2004;291:1325-32.
47. Zelefsky MJ, et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994;29:755-61.
48. Klotz LH, et al. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month posttreatment PSA results. Canadian Urologic Oncology Group. Urology 1999;53:757-63.
49. Bolla M, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
50. Pilepich MV, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-52.
51. Nudell DM, Grossfeld GD, Weinberg VK, Roach M 3rd, Carroll PR. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 1999;54:1049-57.
52. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997;79:235-46.
53. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. Jama 2005;294:238-44.
54. Ryan CJ, Small EJ. Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol 2005;23:8225-31.
55. Small EJ, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025-33.
56. Daskivich TJ, Oh WK. Recent progress in hormonal therapy for advanced prostate cancer. Curr Opin Urol 2006;16:173-8.
57. Eisenberger MA, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.
58. Berry W, Eisenberger M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 2005;10 Suppl 3:30-9.
59. Kucuk O, et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001;58:53-8.
60. Miyake H, Hara I, Eto H. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer. BJU Int 2005;96:791-5.
61. Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 2002;168:542-5.
62. Oh WK. The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 2002;1:81-9.
63. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 2005;55:300-318. Quiz 323-305.
64. Petrylak DP, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
65. Tannock IF, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
66. Kantoff PW, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999;17:2506-13.
67. Akerley W, et al. A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer 2002;94:1654-60.
68. Saad F, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
69. Oefelein MG, Agarwal PK, Resnick MI. Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 2004;171:1525-8.
70. Armstrong AJ, Carducci MA. New drugs in prostate cancer. Curr Opin Urol 2006;16:138-45.
71. Desai P, Jimenez JA, Kao C, Gardner TA. Future innovations in treating advanced prostate cancer. Urol Clin North Am 2006;33:247-72. viii.
72. MacRae EJ, et al. Gene therapy for prostate cancer: current strategies and new cell-based approaches. Prostate 2006;66:470-94.
73. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005;23:8232-41.
74. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61.
75. Sternberg CN. Satraplatin in the treatment of hormone-refractory prostate cancer. BJU Int 2005;96:990-4.
76. Hussain M, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormonerefractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005;23:8724-9.
77. Watt F, et al. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics 2001;73:243-54.
78. Uchida A, O'Keefe DS, Bacich DJ, Molloy PL, Heston WD. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology 2001;58:132-9.
79. http://www.dendreon.com/dndn/provenge.
80. Burch PA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004;60:197-204.
81. Small EJ, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94.
82. www.cellgenesys.com.
83. National Cancer Institute. Clinical trials. Available at: http://www.clinicaltrials.gov.
84. Doehn C, Bohmer T, Jocham D. Technology evaluation: Onyvax-P, Onyvax. Curr Opin Mol Ther 2005;7:511-9.
85. Kaufman HL, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22:2122-32.
86. Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 2005;6:299-310.
87. Pavlenko M, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer 2004;91:688-94.
88. Zlotocha S, et al. A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer. Clin Genitourin Cancer 2005;4:215-8.
89. Milowsky MI, et al. Phase I trial of yttrium-90-labeled antiprostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol 2004;22:2522-31. Epub 2004 Jun 2521.
90. Uzgare AR, Isaacs JT. Prostate cancer: potential targets of antiproliferative and apoptotic signaling pathways. Int J Biochem Cell Biol 2005;37:707-14.
91. Corcoran NM, Costello AJ, Hovens CM. Interfering with cell-survival signalling as a treatment strategy for prostate cancer. BJU Int 2006;97:1149-53.
92. Cancer Genome Project. Cancer Gene Census.web site: http://www.sanger.ac. uk/genetics/CGP/Census.
93. George DJ, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001;7:1932-6.
94. Thomas AL, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005;23:4162-71. Epub 2005 May 4162.
95. Strumberg D, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72. Epub 2004 Dec 2021.
96. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006;11:753-64.
97. Sonpavde G, Hutson TE. New approaches in hormone refractory prostate cancer. Am J Clin Oncol 2006;29:196-201.
98. Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91:13-25.
99. Beekman KW, et al. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer 2006;4:299-302.
100. Pommery N, Henichart JP. Involvement of PI3K/Akt pathway in prostate cancer-potential strategies for developing targeted therapies. Mini Rev Med Chem 2005;5:1125-32.
101. Ayala G, et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004;10:6572-8.
102. Smith MR, Nelson JB. Future therapies in hormone-refractory prostate cancer. Urology 2005;65:9-16. Discussion 17.
103. Beer TM, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003;21:123-8.
104. Gilbert J, Gore SD, Herman JG, Carducci MA. The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 2004;10:4589-96.
105. Zhang Z, Karam J, Frenkel E, Sagalowsky A, Hsieh JT. The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol Oncol 2006;24:152-60.
106. Tolcher AW, et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2005;11:3854-61.
107. Price N, Dreicer R. Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Prostate Cancer 2004;3:141-3.
108. Jimeno A, Carducci M. Atrasentan: targeting the endothelin axis in prostate cancer. Expert Opin Investig Drugs 2004;13:1631-40.
109. Jimeno A, Carducci M. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 2005;5:419-27.
110. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006;107:530-5.
111. Mosca A, Berruti A, Russo L, Torta M, Dogliotti L. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest 2005;28:141-5.
112. Weinstein IB, Joe AK. Mechanisms of disease: Oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006;3:448-57.